Stemedica Cell Technologies, Inc., a leader in adult stem cell development, today announces that it has appointed Riccardo Nisato, MBA, PhD, as Director of Manufacturing and Clinical Business Development of Stemedica International, CH. Dr. Nisato will be responsible for replicating Stemedica’s U.S. based operations to Stemedica’s International’s center based in Lausanne, Switzerland.

A respected biologist, project leader and business consultant in the medical technology field, Dr. Nisato’s specialty is the development of strategic options for cell therapy manufacturing that complies with Swiss Medic standards for Good Manufacturing Practice (GMP) in Switzerland. Dr. Nisato has a Master in Pharmacology from the University Paris V, a Ph.D. in Biology from the University of Geneva and an MBA in the Management of Technology from École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.

“We are delighted to add Dr. Nisato to our Stemedica International team. Our plans to serve Clinical Research Centers outside the United States with in-depth stem cell research, product development, manufacturing and Master Bank product capabilities will be significantly advanced by Dr. Nisato’s leadership and experience. His expertise in the cell manufacturing processes, including his intimate interaction with researchers and clinicians involved in Phase I, Phase II studies and approved treatments derived from fetal and adult cells, combined with his years of consulting for medical technology companies will provide invaluable direction for our international development strategy,” said Roger Howe, Chairman and CFO at Stemedica.

“The prospect that Stemedica International represents for establishing regulatory-approved clinical trials at high-accredited treatment facilities around the world, leading to successful treatment for patients with debilitating conditions, is an invigorating opportunity for me at this point in my career. I have been fortunate to extensively collaborate with researchers and surgeons involved in cell-based clinical trials and approved therapies for skin burn treatments for children and adults, so I am intimately aware of the difference that Stemedica International will make in the future. It’s an honor to be in at ground level, working to build Stemedica into a worldwide leader in the adult stem cell industry,” said Dr. Nisato.

Dr. Nisato will report to Dr. Alex Kharazi, Vice President, Research & Manufacturing for Stemedica International’s partner organization, Stemedica Cell Technologies and to Dr. Nikolai Tankovich, Chairman of Stemedica International and President and Medical Officer of Stemedica Cell Technologies.

“Dr. Nisato has the perfect combination of medical knowledge in pharmacology and cell biology as well as with medically-oriented business development that makes him the perfect choice for this significant new role. We are very fortunate to have attracted his interest and to have brought about this significant appointment. I am excited about extending our solid U.S. work to Europe under Dr. Nisato’s strategic oversight,” said Dr. Tankovich.